Maruho, Toray to Co-develop Antipruritic Agent for Dialysis Patients.Tokyo, Japan, Nov 2, 2005 - (JCNN) - Maruho and TORAY signed an agreement on October 31on the joint development of TRK-820, a candidate compound discovered by TORAY's Pharmaceutical Research Laboratory which a kappa opioid receptor agonist with a different mechanism from existing antipruritic antipruritic /an·ti·pru·rit·ic/ (-proo-rit´ik) preventing or relieving itching, or an agent that does this. an·ti·pru·rit·ic adj. Preventing or relieving itching. agents like antihistamine antihistamine (ăn'tĭhĭs`təmēn), any one of a group of compounds having various chemical structures and characterized by the ability to antagonize the effects of histamine. . Under the agreement terms, the two companies will jointly conduct a phase III trial in Europe, which is intended to treat dialysis patients with uremic uremic pertaining to or emanating from uremia. uremic poisoning see uremia, visceral gout. uremic toxins pruritus pruritus /pru·ri·tus/ (proo-ri´tus) itching.prurit´ic pruritus a´ni intense chronic itching in the anal region. pruritus hiema´lis xerotic eczema. . With this move, the two companies aim to develop a novel agent for urmic pruritus to help improve the quality of life of dialysis patients. Source: JCN http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion